Follow The Filings

NUS Nu Skin Enterprises

Nu Skin Enterprises earnings company data as of 4:47 AM ET 10/24

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 5 Nov EPS 0.21 — —
Rev — — —

Insider trades

Open-market buys and sales by NUS's executives, directors and 10% owners in the last 12 months, from their Form 4s

All NUS insider trades
  • $53K bought by 1 insider
  • $18K sold by 1 insider outside a trading plan
  • $82K sold by 2 insiders under 10b5-1 plans
  1. James M Winett Director
    Planned sale
    $40K 7,203 shares at $5.62 16% of stake
    Traded Jun 2 Filed Jun 3
    ↗
  2. Edwina D Woodbury Director
    Planned sale
    $41K 7,203 shares at $5.70 10% of stake
    Traded Jun 1 Filed Jun 3
    ↗
  3. Laura Nathanson Director
    Sale
    $18K 2,676 shares at $6.73 8.1% of stake
    Traded May 11 Filed May 12
    ↗
  4. Steven Keith Hatchett Chief Product Officer
    Buy
    $53K 5,500 shares at $9.61 +3.4% to stake
    Traded Nov 11, 2025 Filed Nov 12, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 26 stock grants and 11 share withholdings for taxes.

SEC filings

Recent issuer filings from EDGAR, 14 shown.

Filed Form Detail Links
8-K 5.02 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q FORM 10-Q Filing Doc
8-K 5.02,5.07,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
10-Q FORM 10-Q Filing Doc
8-K 5.02 Filing Doc
8-K 2.02,9.01 Filing Doc
DEF 14A 2026 PROXY STATEMENT Filing Doc
DEFA14A 2026 NOTICE OF INTERNET AVAILABILITY Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 1.01,2.03,9.01 Filing Doc
8-K 5.02,9.01 Filing Doc
8-K 5.02,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 6 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.